Jazz's HER2 bispecific snags FDA nod, teeing up showdown with AZ and Daiichi's Enhertu

Jazz's HER2 bispecific snags FDA nod, teeing up showdown with AZ and Daiichi's Enhertu

Submitted by admin on November 21, 2024 - 11:18am
Source: 
Fierce Pharma
News Tags: 
Jazz Pharma
FDA
HER2 Inhibitor
bispecifics
zanidatamab
Headline: 
Jazz's HER2 bispecific snags FDA nod, teeing up showdown with AZ and Daiichi's Enhertu
snippet: 

A bispecific antibody has entered the HER2 fray with a differentiated profile from traditional agents and a chance to challenge AstraZeneca and Daiichi Sankyo’s star antibody-drug conjugate Enhertu.

Do Not Allow Advertisers to Use My Personal information